|

Ensartinib Clinical Trials

5 actively recruiting trials

Also known as: X-396, X-396 capsule

Pipeline

Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

Betta Pharmaceuticals Co., Ltd.2
Sun Yat-sen University1
Peking Union Medical College Hospital1
Hebei Medical University Fourth Hospital1

Indications

Cancer5
Lung Cancer4
Non Small Cell Lung Cancer2
Ensartinib1
Anaplastic Lymphoma Kinase I1171N1

Other5 trials

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Phase 2

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Phase 3

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Phase 2

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.